SOURCE: GrayBug

GrayBug

January 07, 2016 08:00 ET

GrayBug to Present at Biotech Showcase 2016 in San Francisco on January 12

BALTIMORE, MD--(Marketwired - Jan 7, 2016) - GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, announced that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, is slated to present on Tuesday, January 12 at the 8th Annual Biotech Showcase: Investor and Partnering Conference.

Biotech Showcase, held this year from January 11-13 in San Francisco, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

Who: Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer
When: 9:45 am, Tuesday, January 12, 2016; Track E
Where: Parc 55 Hilton Hotel, Room Davidson
55 Cyril Magnin Street, San Francisco

About GrayBug, Inc.
GrayBug was founded in September 2011 as a spin-out of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to a few times per year (as few as twice per year). These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products. GrayBug is initially focused on developing its own products for the treatment of wet AMD and glaucoma. 

GrayBug's technologies were co-developed by GrayBug founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with GrayBug cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD. The technologies were licensed from Johns Hopkins University. For more information, please visit www.graybug.com.

Contact Information

  • GrayBug, Inc. Corporate
    Jeffrey L. Cleland, PhD
    650-868-5853
    Email Contact

    or

    GrayBug, Inc. Media
    Debra Bannister
    530-676-7373
    Email Contact